Pain Therapeutics’ Remoxy Is More Abuse-Resistant Than Other Oxycodone Formulations, FDA Panel Suggests

Approval may depend on FDA’s confidence that the firm’s proposed REMS can adequately monitor for abuse – a subject of apparent debate within FDA.